Neuraxpharm Group, a European company that focuses on treating brain and nervous system disorders, has teamed up with mjn-neuro, a start-up that makes medical devices. They are planning to release EPISERAS®, a new digital health solution designed to predict when epileptic seizures are likely to happen.
EPISERAS® is a non-invasive device that records brain activity using a small, wearable earpiece sensor. It uses artificial intelligence to analyze the brain’s electrical patterns as well as sends an alert minutes before a seizure occurs when the risk is high. This gives patients and caregivers valuable time to prepare or move to a safe place. The device works with a mobile app that shows seizure risk data and alerts.
This solution is aimed at patients with drug-resistant epilepsy and is designed to improve safety and quality of life by preventing accidents. EPISERAS® has been approved in Europe as a medical device and has received the CE mark and UKCA certification. A clinical study called SERAS-Home_RWD is currently taking place in Spain, the UK, and Germany, with data expected to be published soon.
As per Coherent Market Insights, the Digital Health Market will grow at an 18.4% compound annual growth rate (CAGR) from 2025 to 2032, from USD 350.42 Bn in 2025 to around USD 1,143.01 Bn by 2032. Technology and healthcare are converging to rapidly transform the digital health market. Companies and providers are actively deploying innovations like telemedicine, mobile health apps, wearable devices, as well as AI-driven platforms, to revolutionize how care is delivered, monitored, and managed.
Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: "At Neuraxpharm, we are dedicated to improving the lives of people with CNS disorders through continuous innovation and strong partnerships. With this launch, we are taking another important step in our journey to improve the daily lives of people with epilepsy. This breakthrough embodies our commitment to digital personalized CNS care, helping patients feel safer, more in control, and better supported. By combining our deep therapeutic expertise with cutting-edge technology, we are making our vision of holistic CNS care a reality. Our goal is to expand access to effective care that enhances safety, autonomy, and long-term well-being for patients."
David Blánquez, Chief Executive Officer and Co-Founder of mjn-neuro, added, "Our team has been developing this pioneering project for more than ten years, and thanks to the results obtained from several clinical studies, mjn-neuro has successfully demonstrated solid clinical evidence supporting its effectiveness. We are now focused on ensuring that patients can benefit from this innovation that will help improve their quality of life and reduce accidents caused by seizures. Working with Neuraxpharm on the European market launch is a key step in bringing this breakthrough solution to those who need it most."
Source:
News: Neuraxpharm Group
